曼月乐治疗子宫腺肌病患者月经量过多的临床效果和安全性分析  

The Clinical Efficacy and Safety of Mirena Treatment for Uterine Adenomyosis in Menorrhagia

作　　者：吴晚英[1] WU Wanying(Wuzhou Red Cross Hospital,Wuzhou 543002,Chin)

机构地区：[1]梧州市红十字会医院,广西梧州543002

出　　处：《中外医学研究》2018年第13期12-14,共3页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:探讨曼月乐治疗子宫腺肌病患者月经量过多的临床效果和安全性分析。方法:选取笔者所在医院2014年1月-2016年1月收治的100例子宫腺肌病患者为本研究对象,随机分为观察组和对照组,每组50例。对照组患者采用米非司酮治疗,观察组患者采用放置曼月乐的方式进行治疗。比较两组患者治疗前后的月经量、子宫体积和子宫内膜厚度、痛经程度及不良反应,结果:与治疗前相比,两组患者治疗3、6、12个月后的月经量明显较少(P<0.05),且观察组的月经量明显低于对照组(P<0.05);观察组患者的痛经VAS评分明显低于对照组(P<0.05)。观察组子宫体积更小、子宫内膜厚度更薄,差异均有统计学意义(P<0.05)。治疗3个月时,观察组不良反应发生率明显低于对照组,差异有统计学意义(X^2=2.102,P<0.05),治疗12个月时,观察组不良反应发生率略低于对照组,但组间比较差异无统计学意义(X^2=0.511,P>0.05)。结论:曼月乐治疗子宫腺肌病的效果显著,可减少患者的月经量和痛经程度,缩小子宫体积和子宫内膜厚度,值得临床推广应用。Objective：To investigate the clinical efficacy and safety of Mirena therapy in patients with adenomyosis.Method：A total of 100 patients with adenomyosis admitted to our hospital from January 2014 to January 2016 were randomly divided into the observation group and the control group,50 case in each group.The patients in the control group were treated with Mifepristone and the patients in the observation group were treated with Mirenaring.The two groups of menstrual volume,uterine volume and endometrial thickness,dysmenorrhea degree and adverse reactions were compared before and after treatment.Result：Compared with the control group, the menstrual volume in the observation group was significantly lower than that in the control group（P〈0.05）,and the menstrual volume in the observation group was significantly lower than that in the control group（P〈0.05）.Compared with the control group, the uterine volume and endometrial thickness of the observation group were significantly smaller than those of the observation group（P〈0.05）.At the 3 months of treatment,the incidence of adverse reactions in the observation group was significantly lower than the control group,the difference was statistically significant（ X^2=2.102,P〈0.05）.The incidence of adverse reactions in the observation group was slightly lower than that of the control group at 12 months,but there was no significant difference between the two groups（ X^2=0.511,P〉0.05）.Conclusion：Mirena is effective and safe in the treatment of adenomyosis.It can effectively relieve the menstrual flow and dysmenorrhea,reduce the volume of the uterusand the thickness of the endometrium.It is worth of popularizing and applying on clinic.

关 键 词：子宫腺肌病 曼月乐 月经量 临床疗效 安全性 

分 类 号：R711.71[医药卫生—妇产科学]